We’ve recently updated our valuation analysis.

Vivoryon Therapeutics Valuation

Is VVY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VVY?

Other financial metrics that can be useful for relative valuation.

VVY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue18x
Enterprise Value/EBITDA-15.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does VVY's PS Ratio compare to its peers?

VVY PS Ratio vs Peers
The above table shows the PS ratio for VVY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.7x
PHARM Pharming Group
3.3x12.8%€689.6m
A228760 Genomictree
6.1xn/a₩180.6b
PSTX Poseida Therapeutics
7.6x-17.6%US$268.9m
OYST Oyster Point Pharma
4.9x51.2%US$157.0m
VVY Vivoryon Therapeutics
19.3x65.1%€208.2m

Price-To-Sales vs Peers: VVY is expensive based on its Price-To-Sales Ratio (19.3x) compared to the peer average (5.7x).


Price to Earnings Ratio vs Industry

How does VVY's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Sales vs Industry: VVY is expensive based on its Price-To-Sales Ratio (19.3x) compared to the European Biotechs industry average (13.1x)


Price to Sales Ratio vs Fair Ratio

What is VVY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VVY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio19.3x
Fair PS Ratio187.2x

Price-To-Sales vs Fair Ratio: VVY is good value based on its Price-To-Sales Ratio (19.3x) compared to the estimated Fair Price-To-Sales Ratio (187.2x).


Share Price vs Fair Value

What is the Fair Price of VVY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VVY's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VVY's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies